Tocopherols and Alpha Lipoic Acid Treatment Chronic Kidney Disease (TALAT)
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
Oxidative stress and acute phase inflammation are now recognized to be highly prevalent in
both the chronic kidney disease (CKD; pre-dialysis) and end stage renal disease (ESRD; on
hemodialysis) populations, and several lines of evidence point to their contribution in the
development of atherosclerosis. Biomarkers of the inflammatory state such as C-reactive
protein (CRP) and interleukin-6 are robust predictors of cardiovascular events and death in
these two populations. The uremic state is characterized by retention of oxidized solutes
including reactive aldehyde groups and oxidized thiol groups. It has recently been
demonstrated that initiation of maintenance hemodialysis does not improve biomarkers of
oxidative stress or inflammation, suggesting that dialysis alone is inadequate to control the
atherosclerotic uremic metabolic state. In this study we hypothesize that administration of
antioxidant therapy will decrease biomarkers of acute phase inflammation and oxidative stress
in patients with Stage III and IV CKD.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Treatments:
alpha-Tocopherol Thioctic Acid Tocopherols Tocotrienols Vitamin E